Smith, Moore & Co’s Medifast MED Stock Holding History

Smith, Moore & Co’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,500	Closed	-$377K	–	249
2017 Q1	$377K	Hold	8,500	–	–	0.14%	147
2016 Q4	$354K	Hold	8,500	–	–	0.13%	149
2016 Q3	$321K	Hold	8,500	–	–	0.13%	152
2016 Q2	$283K	Buy	+8,500	New	+$274K	0.12%	160
2015 Q3	–	Sell	-10,597	Closed	-$342K	–	171
2015 Q2	$342K	Sell	10,597 -13,994	-57%	-$444K	0.17%	112
2015 Q1	$737K	Sell	24,591 -7,306	-23%	-$232K	0.39%	45
2014 Q4	$1.07M	Buy	31,897 +18,047	+130%	+$562K	0.57%	30
2014 Q3	$455K	Buy	+13,850	New	+$425K	0.25%	77

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Smith, Moore & Co's MED Position: Q2 2017 in Review

Smith, Moore & Co sold out of Medifast (MED) in Q2 2017, closing a stake of 8,500 shares — an estimated $377K sold.

Smith, Moore & Co first reported a position in MED in Q3 2014 and held it in 8 quarters. The position peaked at $1.07M in Q4 2014. 161 funds tracked by Wall St. Rank hold MED as of Q2 2017.

Smith, Moore & Co reported no remaining Medifast position as of Q2 2017 after selling out during the quarter.
Smith, Moore & Co sold 8,500 Medifast shares in Q2 2017, an estimated $377K.
Smith, Moore & Co first reported a position in Medifast in Q3 2014 and held it in 8 quarters.
Smith, Moore & Co's Medifast position peaked at $1.07M in Q4 2014.
161 funds tracked by Wall St. Rank held Medifast as of Q2 2017.

Based on Smith, Moore & Co's 13F filing for Q2 2017, filed 11 Aug 2017.